Metabolic acidosis

New US product, ORMALVI™ (dichlorphenamide) tablets, launches for Primary Periodic Paralysis (PPP) treatment

Retrieved on: 
onsdag, maj 8, 2024
FDA, General Health, Pharmaceutical, Health, Fetus, Cardiomyopathy, Torrent, Acidosis, Respiratory acidosis, Full, Diclofenamide, Risk, Pregnancy, Cognitive disorder, Milk, Aspirin, Metabolic acidosis, Dysgeusia, Hyperkalemia, Aplastic anemia, Partnership, PPP, Agranulocytosis, Anorexia nervosa, Human, Carbonic anhydrase inhibitor, SVP, Tablet, Incidence, Patient, Nursing, Lethargy, Serum, Hyperkalemic periodic paralysis, Diagnosis, Myopathy, Hypokalemic periodic paralysis, Paralysis, Paresthesia, Cycle, Stevens–Johnson syndrome, Hypokalemia, Quality of life, Argyreia nervosa, Sulfonamide, Coma, Pharmaceutical industry

We want to provide them with the support that they require to effectively manage their PPP.

Key Points: 
  • We want to provide them with the support that they require to effectively manage their PPP.
  • ORMALVI™ is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
  • Simply Stated: Research Updates in Periodic Paralysis - Quest | Muscular Dystrophy Association [online] Available at: https://mdaquest.org/simply-stated-research-updates-in-periodic-paralysis Accessed 23 Nov. 2023.
  • The impact of permanent muscle weakness on quality of life in periodic paralysis: a survey of 66 patients.

Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Retrieved on: 
måndag, januari 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Kidney, Metabolic acidosis, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Retrieved on: 
måndag, januari 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Metabolic acidosis, Kidney, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Retrieved on: 
måndag, januari 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Metabolic acidosis, Kidney, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
måndag, januari 8, 2024
Lithium, UGT, Risk, Digoxin, Shanda, Hypotension, FDA, SGLT1, Type 2 diabetes, Acute kidney injury, Congress, Pyelonephritis, Conference, Fever, Ketoacidosis, Pregabalin, Pregnancy, Pain, Assessment, Gabapentin, Tenderness, New Drug Application, Amber Grid, HCM, Common, SGLT2, PROGRESS, Hypertrophic cardiomyopathy, Diabetes, Kidney, Heart failure, Dialysis, History, Patient, Prescription, Type, Neuropathic pain, Webcast, Insulin, T2DM, EGFR, Erythema, T1DM, Hypoglycemia, Partnership, Contraindication, Diarrhea, NDA, Incidence, Swelling, Urinary tract infection, Hospital, Chronic kidney disease, Internationalized domain name, Metabolic acidosis, Creatinine, Growth, Lactation, Pharmaceutical industry

THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024.

Key Points: 
  • THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024.
  • “Lexicon achieved major advancements in 2023 in its business and pipeline of pharmaceutical innovations,” said Lonnel Coats, chief executive officer and director of Lexicon.
  • The company will also focus on ensuring a strong ongoing awareness of INPEFA in the medical community through medical publications and congress presence.
  • Company to Present at J.P. Morgan Healthcare Conference Thursday, January 11, 2024 at 10:30am PST (1:30pm ET)
    Lonnel Coats, Lexicon’s chief executive officer, will make a company presentation.

Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea

Retrieved on: 
onsdag, december 6, 2023
Obstructive sleep apnea, Deficit spending, Depression, Disease, Ageing, Blood, Claustrophobia, Accident, Dronabinol, Death, Workplace, Metabolic acidosis, Noise, Conditional sentence, Sleep, Amnesia, Patient, Diagnosis, Cardiovascular disease, PAP, Safety, CO2, AHI, PSG, Somnolence, Acetazolamide, Polysomnography, Judgement, Pharmaceutical industry

Obstructive sleep apnea (OSA) is characterised by a narrowing or obstruction of the upper airway during sleep, which interrupts breathing resulting in decreased oxygen uptake and poor sleep quality.

Key Points: 
  • Obstructive sleep apnea (OSA) is characterised by a narrowing or obstruction of the upper airway during sleep, which interrupts breathing resulting in decreased oxygen uptake and poor sleep quality.
  • Incannex has designed IHL-42X, a combination of dronabinol (synthetic THC) and acetazolamide, for treatment of OSA.
  • A video presentation of IHL-42X for the treatment of OSA has been uploaded to the Incannex website, link here: https://www.incannex.com/clinical-trail/ihl-42x-osa/ .
  • This gave Incannex the confidence to proceed with a multisite Phase 2/3 clinical trial further investigating safety and efficacy of IHL-42X in patients with OSA.

Holiday Pet Dangers

Retrieved on: 
onsdag, november 15, 2023
CNS, Xanthine, Holiday, Vomiting, Poisoning, Pet, Urine, Blood pressure, Cat, Toxicity, THC, Toxicology, Coma, Risk, Tremor, Arrhythmia, Chocolate, Hypoglycemia, Xylitol, Metabolic acidosis, Ataxia, New Year's Eve, Milk, Heart rate, Animal, Acute liver failure, Oxycodone, Ethanol, Hypoventilation, Friends, Alaskan Malamute, Caffeine, Seizure, Golden, Kidney failure, Diarrhea, Survival, Death, Tachycardia, Happiness, Paracetamol, Classic, Family, Nightmare, Mouth, Sodium chloride, Central nervous system, Failure, Common, Dog, Hypothermia, Lethargy, Radar, Theobromine, Fireworks, Liquor, Tourism, Makita

MINNEAPOLIS, Nov. 15, 2023 /PRNewswire/ -- The holidays are best spent with family and friends, not taking a trip to the animal hospital. With the trifecta of Thanksgiving, Christmas and New Years Eve coming up, the toxicology experts at Pet Poison Helpline want to warn pet lovers about the many dangers that face pets during this festive season.

Key Points: 
  • With the trifecta of Thanksgiving, Christmas and New Years Eve coming up, the toxicology experts at Pet Poison Helpline want to warn pet lovers about the many dangers that face pets during this festive season.
  • Meinke also contacted Pet Poison Helpline, who then worked with the medical team at BluePearl to identify the lily, diagnose and treat his pets.
  • "Many holiday treats include chocolate, and are often left sitting out on counters and dinner tables," said Dr. Schmid.
  • This year, we want pet lovers to remember the holidays for all the joy and happiness, not an emergency room visit."

Avanzanite Bioscience Expands Partnership With Advicenne in Additional European Countries

Retrieved on: 
onsdag, oktober 18, 2023
Health, Other Health, Other Science, Pharmaceutical, Science, Biotechnology, Metabolic acidosis, Rickets, Multimedia, Growth, Urine, Acid, Kidney, Partnership, Kidney disease, Blood, Traction, Renal tubular acidosis, Patient, Pharmaceutical industry

Avanzanite Bioscience B.V. (“Avanzanite” or the “Company”), a specialty pharmaceutical company with a corporate mission of boosting orphan drug access and unlocking their full potential in European markets, today announced that it has expanded its commercial partnership with Paris-based specialty pharmaceutical company Advicenne for Sibnayal®.

Key Points: 
  • Avanzanite Bioscience B.V. (“Avanzanite” or the “Company”), a specialty pharmaceutical company with a corporate mission of boosting orphan drug access and unlocking their full potential in European markets, today announced that it has expanded its commercial partnership with Paris-based specialty pharmaceutical company Advicenne for Sibnayal®.
  • Today’s announcement extends Avanzanite’s exclusive commercialization and distribution rights into three additional European countries, including Ireland, Cyprus and Malta.
  • The condition leads to stunted growth in children, brittle bones or rickets, kidney stones and life-threatening hypokalemia.
  • Announced in February 2023 , the original geographic scope of the partnership included Germany, Austria, Switzerland and Greece.

Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer

Retrieved on: 
måndag, oktober 16, 2023
B.A, Metabolic acidosis, MBA, Engineering, Perrigo, Kite Pharma, Business, Dartmouth College, Organization, Stanford Graduate School of Education, Goldman Sachs, Biotechnology, Cancer, Pfizer, Stanford Graduate School of Business, Therapy, Chronic kidney disease, CAR, SAN, Patient, Management, Economics

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, has appointed Geoffrey Parker as Executive Vice President, Chief Financial Officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, has appointed Geoffrey Parker as Executive Vice President, Chief Financial Officer.
  • Mr. Parker will oversee the Company’s financial operations and business strategy and will serve as a member of the Leadership Team.
  • “I am excited to join Allogene during this pivotal time in the company’s evolution,” said Mr. Parker.
  • In addition, Mr. Parker currently serves as a member of the board of directors of Better Therapeutics and of Perrigo Company plc.

Outcomes Data Reveal Significant Impact of Etiometry Utilization in Liberating Patients from Invasive ICU Treatments

Retrieved on: 
måndag, augusti 28, 2023
Managed Care, Software, Research, Technology, Hospitals, Health Technology, Surgery, Clinical Trials, Science, Cardiology, Nursing, Practice Management, Health, Hospice and palliative medicine, Risk, University of Alabama, Probability, University, HLA, Lactic acid, Perfusion, MSHA, Quality, Associate, Annals of Pediatric Cardiology, Harvard Medical School, Charles Mullins (pediatric cardiologist), Congress, Hospital, ERT, Metabolic acidosis, Assistant professor, Medical director, Patient, Division, Algorithm, Disease, ICU, Analytics, FDA, Weaning, MPH, Pelvic floor dysfunction, Automation, Medical device, Pharmaceutical industry, Pediatrics, MD

Etiometry’s Risk Analytics provide an individualized assessment of the patient’s condition, bringing attention to patients who need it most and revealing insight into the cause of potential deterioration or improvement to a patient's state.

Key Points: 
  • Etiometry’s Risk Analytics provide an individualized assessment of the patient’s condition, bringing attention to patients who need it most and revealing insight into the cause of potential deterioration or improvement to a patient's state.
  • Extubation failure is associated with significant morbidity, including prolonged total ventilation time and longer hospital length of stay.
  • The findings reveal the new automated standardized workflow in Etiometry informed data-driven decisions leading to an 18% reduction of time with vasoactive infusions.
  • The data are compelling, especially in terms of how our clinical intelligence can enhance patient care,” said Shane Cooke, CEO of Etiometry.